Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

August 13, 2020

After previous losses, Covetrus reports $54M earnings for Q2

Portland-based Covetrus Inc. (Nasdaq: CVET) appears to be turning around recent financial performance, reporting an uptick in second-quarter revenue and earnings Tuesday.

The animal-health technology and services company, which struggled last year amid leadership changes and recorded a widening net loss earlier this year, recorded net sales of $1.03 billion, an increase of 2% year-over-year for the three months ended June 30.

Covetrus’ net income was $54 million for the quarter, or 40 cents per share, compared to a net loss of $10 million, or 9 cents per share, in the second quarter of 2019. For the first quarter of 2020, the company reported a loss of $33 million.

Covetrus said in the news release that the “primary driver” of this year’s Q2 earnings was a $70 million after-tax gain on the sale of a German subsidiary, scil animal care.

In addition, organic net sales increased 5% year-over-year, due to growth in the company's prescription management and supply chain businesses.

At quarter-end, the company had $414 million in cash and cash equivalents, $1.14 billion in term loan debt, and no borrowings outstanding on its $300 million revolving credit line.

“I am extremely proud of our team’s exceptional efforts and accomplishments during the second quarter to support our customers around the globe during COVID-19,” said Ben Wolin, Covetrus president and CEO.

“While uncertainties tied to the global pandemic and the pace and recovery of our end-market remain, continued investments in our organizational health, innovation and customer success puts us in a strong position to capitalize on our strategic opportunities and to deliver shareholder value in the quarters and years ahead.”

Sign up for Enews

Mainebiz web partners

Related Content

0 Comments

Register for free to read more articles.

Register Now

Already have an online account? Login

To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy

Allow Cookies